Seoul: Samsung Biologics Co. on Wednesday reported its second-quarter net profit of 324.4 billion won (US$235.1 million), marking a 2 percent increase from the previous year. The company's financial performance during this quarter highlights its continued growth despite not meeting market expectations.

According to Yonhap News Agency, the company's regulatory filing revealed an operating profit for the April-June period of 475.6 billion won, reflecting a 9.5 percent increase compared to the same period last year. Meanwhile, sales surged by 11.5 percent, reaching 1.28 trillion won.

Despite these positive figures, Samsung Biologics' earnings fell short of market predictions. Analysts had anticipated a net profit of 354.8 billion won, based on a survey conducted by Yonhap Infomax, the financial data firm of Yonhap News Agency. The discrepancy between actual results and market expectations suggests a gap in forecasting and the company's performance metrics.